MARKET

STOK

STOK

Stoke Therapeutics
NASDAQ
29.46
-1.92
-6.12%
After Hours: 29.46 0 0.00% 17:19 07/13 EDT
OPEN
31.51
PREV CLOSE
31.38
HIGH
31.60
LOW
29.41
VOLUME
580.46K
TURNOVER
--
52 WEEK HIGH
40.22
52 WEEK LOW
11.66
MARKET CAP
1.83B
P/E (TTM)
-10.4176
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Oncolytics Biotech (ONCY)
TipRanks · 12h ago
Stoke Therapeutics names Thomas McCauley chief scientific officer
PUBT · 18h ago
STOKE THERAPEUTICS APPOINTS THOMAS MCCAULEY, PH.D., AS CHIEF SCIENTIFIC OFFICER
Reuters · 18h ago
Weekly Report: what happened at STOK last week (0706-0710)?
Weekly Report · 19h ago
Stoke Therapeutics Price Target Announced at $44.00/Share by Goldman Sachs
Dow Jones · 19h ago
Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44
Benzinga · 19h ago
Stoke Therapeutics initiated with a Buy at Goldman Sachs
TipRanks · 20h ago
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
Barchart · 23h ago
More
About STOK
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Webull offers Stoke Therapeutics Inc stock information, including NASDAQ: STOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STOK stock methods without spending real money on the virtual paper trading platform.